What type of study is this?

This is a Literature Review study.

September 28, 2025

Non-human leukocyte antigen antibodies in kidney transplantation: pathogenic mechanisms, detection methods, and clinical implications

IOInseong OhSeoul National University ESEun Young SongSeoul National University

Key Points

Non-HLA antibodies contribute to kidney graft injury through both complement-dependent and independent mechanisms, affecting transplant outcomes.
Detection methods include traditional assays and multiplex bead arrays; however, standardization of these methods remains a challenge.
Antibodies targeting angiotensin II type 1 receptor and other antigens play significant roles in exacerbating microvascular inflammation in grafts.
Integrating non-HLA antibody evaluations with multiomics data may improve immunological risk assessment for kidney transplant recipients.

Abstract

The importance of non-human leukocyte antigen (HLA) antibodies in transplant immunology has become increasingly evident, as their pathogenic role in kidney allograft injury is being clarified beyond the well-established effects of donor-specific anti-HLA antibodies. This review summarizes current evidence regarding antigenic targets, pathogenic mechanisms, detection platforms, and clinical implications of non-HLA antibodies in kidney transplantation. Major antigenic targets include angiotensin II type 1 receptor (AT1R), endothelin A receptor (ETAR), major histocompatibility complex class I-related chain A (MICA), vimentin, perlecan fragment LG3 (LG3), collagen, and fibronectin. These contribute to graft injury through both complement-dependent mechanisms (e.g., LG3, MICA) and complement-independent pathways, such as G protein-coupled receptor agonism by AT1R/ETAR and natural killer cell-mediated antibody-dependent cellular cytotoxicity, frequently acting together with HLA antibodies to exacerbate microvascular inflammation. Detection methods range from traditional cell-based assays to high-throughput multiplex bead arrays. However, lack of assay standardization and variability in interpretation remain major barriers to clinical implementation. Approaches such as assessing antibody burden and profiling antibody signatures using multiplex platforms show promise for enhancing immunological risk stratification, although further research and multicenter validation are required. Integrating non-HLA with HLA antibody evaluation, supported by standardized protocols and incorporation of multiomics data, may improve prognostication, guide personalized immunosuppressive strategies, and ultimately enhance kidney transplant outcomes.

Ask AI

Helpful

Bookmark

View Full Paper